Connect Biopharma Holdings Ltd
CNTB
Closed
$2.29
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 64 full-time employees. The company went IPO on 2021-03-19. The firm is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The firm has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Key stats
Open
$2.42
Volume
444.96K
Market cap
$148.62M
Prev. close
$2.36
Impl / hst vl
-
Open interest
$0.00
$2.25
Day’s Range
$2.44
$1.92
52W Range
$3.82
Valuation
0
Valuation score
Strongly Overvalued
P/E
-
P/S
686.39
P/B
3.75
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
-
Income growth
-10.90%
FCF growth
-0.52
Analysts estimates
Consensus rating
Buy
The average rating from top 8 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$7.27
The top 10 analysts forecasts that 12-month price may increase by 217.36%, with a low of $4.04 and a high of $10.50
$4.04
Low
$7.27
Avg
$10.50
High
Current price
Earnings
Q2 ‘26 revenue
$2.77M
Q2 ‘26 net income
-$17.28M
Revenue
Net income
Previous EPS
-$0.34
Estimate EPS
-$0.32
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply